253 related articles for article (PubMed ID: 29160048)
1. From biodegradable polymers to bioresorbable vascular scaffolds: available evidence in the era of new-generation drug-eluting stents.
Magliulo F; Piccolo R; Franzone A; Esposito G; Danzi GB
Minerva Cardioangiol; 2018 Jun; 66(3):246-261. PubMed ID: 29160048
[TBL] [Abstract][Full Text] [Related]
2. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
[TBL] [Abstract][Full Text] [Related]
3. A new generation of drug-eluting stents: Indications and outcomes of bioresorbable vascular scaffolds.
Waksman R
Cleve Clin J Med; 2017 Dec; 84(12 Suppl 4):e20-e24. PubMed ID: 29281608
[TBL] [Abstract][Full Text] [Related]
4. From drug eluting stents to bioresorbable scaffolds; to new horizons in PCI.
Tenekecioglu E; Bourantas C; Abdelghani M; Zeng Y; Silva RC; Tateishi H; Sotomi Y; Onuma Y; Yılmaz M; Serruys PW
Expert Rev Med Devices; 2016; 13(3):271-86. PubMed ID: 26782080
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Durable-Polymer Zotarolimus-Eluting and Biodegradable-Polymer Biolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease: 3-Year Clinical Outcomes in the Randomized SORT OUT VI Trial.
Raungaard B; Christiansen EH; Bøtker HE; Hansen HS; Ravkilde J; Thuesen L; Aarøe J; Villadsen AB; Terkelsen CJ; Krusell LR; Maeng M; Kristensen SD; Veien KT; Hansen KN; Junker A; Madsen M; Andersen SL; Jensen SE; Jensen LO;
JACC Cardiovasc Interv; 2017 Feb; 10(3):255-264. PubMed ID: 28109874
[TBL] [Abstract][Full Text] [Related]
6. Drug-eluting stents to prevent stent thrombosis and restenosis.
Im E; Hong MK
Expert Rev Cardiovasc Ther; 2016; 14(1):87-104. PubMed ID: 26567863
[TBL] [Abstract][Full Text] [Related]
7. Novel bioabsorbable polymer and polymer-free metallic drug-eluting stents.
Nogic J; McCormick LM; Francis R; Nerlekar N; Jaworski C; West NEJ; Brown AJ
J Cardiol; 2018 May; 71(5):435-443. PubMed ID: 29338896
[TBL] [Abstract][Full Text] [Related]
8. Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial.
Kandzari DE; Mauri L; Koolen JJ; Massaro JM; Doros G; Garcia-Garcia HM; Bennett J; Roguin A; Gharib EG; Cutlip DE; Waksman R;
Lancet; 2017 Oct; 390(10105):1843-1852. PubMed ID: 28851504
[TBL] [Abstract][Full Text] [Related]
9. A propensity score-matched comparison of biodegradable polymer vs second-generation durable polymer drug-eluting stents in a real-world population.
Zhao YJ; Teng M; Khoo AL; Ananthakrishna R; Yeo TC; Lim BP; Loh JP; Chan MY
Cardiovasc Ther; 2018 Apr; 36(2):. PubMed ID: 29316284
[TBL] [Abstract][Full Text] [Related]
10. Long-term patient benefit with biodegradable polymer biolimus eluting stent.
Corti R
Minerva Cardioangiol; 2012 Dec; 60(6):629-36. PubMed ID: 23147439
[TBL] [Abstract][Full Text] [Related]
11. Second generation drug-eluting stents: a focus on safety and efficacy of current devices.
Spione F; Brugaletta S
Expert Rev Cardiovasc Ther; 2021 Feb; 19(2):107-127. PubMed ID: 33417509
[No Abstract] [Full Text] [Related]
12. Performance of the Orsiro Hybrid drug-eluting stent in high-risk subgroups.
Iglesias JF; Muller O; Zuffi A; Eeckhout E
Minerva Cardioangiol; 2016 Feb; 64(1):55-73. PubMed ID: 26542119
[TBL] [Abstract][Full Text] [Related]
13. Factors Influencing 1st and 2nd Generation Drug-Eluting Stent Performance: Understanding the Basic Pharmaceutical Drug-in-Polymer Formulation Factors Contributing to Stent Thrombosis Do We Really Need to Eliminate the Polymer?
Srdanovic I
J Pharm Pharm Sci; 2021; 24():435-461. PubMed ID: 34499602
[TBL] [Abstract][Full Text] [Related]
14. Five-year outcomes from a trial of three limus-eluting stents with different polymer coatings in patients with coronary artery disease: final results from the ISAR-TEST 4 randomised trial.
Kufner S; Byrne RA; Valeskini M; Schulz S; Ibrahim T; Hoppmann P; Schneider S; Laugwitz KL; Schunkert H; Kastrati A;
EuroIntervention; 2016 Mar; 11(12):1372-9. PubMed ID: 25405657
[TBL] [Abstract][Full Text] [Related]
15. Bioresorbable vascular scaffolds for the treatment of coronary artery disease: what have we learned from randomized-controlled clinical trials?
Rizik DG; Hermiller JB; Simonton CA; Klassen KJ; Kereiakes DJ
Coron Artery Dis; 2017 Jan; 28(1):77-89. PubMed ID: 27561169
[TBL] [Abstract][Full Text] [Related]
16. New-Generation Coronary Stents: Current Data and Future Directions.
Kalra A; Rehman H; Khera S; Thyagarajan B; Bhatt DL; Kleiman NS; Yeh RW
Curr Atheroscler Rep; 2017 Mar; 19(3):14. PubMed ID: 28220461
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes of biodegradable polymer versus durable polymer drug-eluting stents in patients with diabetes a pooled analysis of individual patient data from 3 randomized trials.
de Waha A; Stefanini GG; King LA; Byrne RA; Serruys PW; Kufner S; Meier B; Jüni P; Kastrati A; Windecker S
Int J Cardiol; 2013 Oct; 168(6):5162-6. PubMed ID: 23993323
[TBL] [Abstract][Full Text] [Related]
18. Bioresorbable vascular scaffolds for the treatment of coronary artery disease: Clinical outcomes from randomized controlled trials.
Rizik DG; Hermiller JB; Kereiakes DJ
Catheter Cardiovasc Interv; 2016 Nov; 88(S1):21-30. PubMed ID: 27797464
[TBL] [Abstract][Full Text] [Related]
19. Current status of drug-eluting stents.
Räber L; Windecker S
Cardiovasc Ther; 2011 Jun; 29(3):176-89. PubMed ID: 20370793
[TBL] [Abstract][Full Text] [Related]
20. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials.
Stefanini GG; Byrne RA; Serruys PW; de Waha A; Meier B; Massberg S; Jüni P; Schömig A; Windecker S; Kastrati A
Eur Heart J; 2012 May; 33(10):1214-22. PubMed ID: 22447805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
